Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report).
Confident Investing Starts Here:
Quince Therapeutics (QNCX)
In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17.
According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target.
Moderna (MRNA)
In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46.
According to TipRanks.com, Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc.
Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
Analysts' Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quince Therapeutics (QNCX – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: Quince Therapeutics (QNCX) In a report issued on June 4, Jason McCarthy from Maxim Group maintained a Buy rating on Quince Therapeutics, with a price target of $6.00. The company's shares closed last Friday at $1.17. According to McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.2% and a 28.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quince Therapeutics with a $6.67 average price target. Moderna (MRNA) In a report released today, Matt Phipps from William Blair reiterated a Hold rating on Moderna. The company's shares closed last Friday at $27.46. According to Phipps is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.1% and a 41.7% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Janux Therapeutics Inc. Currently, the analyst consensus on Moderna is a Hold with an average price target of $49.29, an 88.1% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
19 hours ago
- Business Insider
Analysts Offer Insights on Consumer Cyclical Companies: Five Below (FIVE) and Autoliv (ALV)
Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Five Below (FIVE – Research Report) and Autoliv (ALV – Research Report). Confident Investing Starts Here: Five Below (FIVE) Barclays analyst Seth Sigman maintained a Hold rating on Five Below on June 5 and set a price target of $120.00. The company's shares closed last Friday at $127.35. According to Sigman 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.0% and a 53.9% success rate. Sigman covers the NA sector, focusing on stocks such as Driven Brands Holdings, Floor & Decor Holdings, and Advance Auto Parts. Five Below has an analyst consensus of Moderate Buy, with a price target consensus of $118.63, which is a -7.0% downside from current levels. In a report issued on May 28, Citi also maintained a Hold rating on the stock with a $121.00 price target. Autoliv (ALV) Kepler Capital analyst Alexandre Raverdy maintained a Buy rating on Autoliv on June 5 and set a price target of $100.00. The company's shares closed last Friday at $105.62. According to Raverdy is ranked #5408 out of 9607 analysts. Autoliv has an analyst consensus of Strong Buy, with a price target consensus of $111.31, a 4.8% upside from current levels. In a report issued on May 28, UBS also maintained a Buy rating on the stock with a $123.00 price target.
Yahoo
a day ago
- Yahoo
S&P 500 Gains and Losses Today: Lululemon Stock Falls as Forecasts Reflect Consumer Caution
The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite tariff-related concerns. After retreating from record highs over the past few sessions, shares of data analytics firm Palantir bounced back, boosted by a signal of robust AI demand. Shares of Lululemon plummeted after the apparel maker cut its outlook for the current quarter and the full year, citing soft consumer U.S. equities indexes pushed higher to close out the trading week. The Bureau of Labor Statistics reported that the U.S. economy added 139,000 jobs in May, topping economists' forecasts and helping alleviate concerns about a tariff-driven slowdown in the labor market. The S&P 500 gained 1% on Friday, closing above the 6,000-point level for the first time since February. The Dow was up 1.1%, while the Nasdaq jumped 1.2%. Shares of big data analytics software provider Palantir Technologies (PLTR) popped 6.5% higher, securing the top daily performance in the S&P 500. Positivity around its expanding government business helped lift Palantir to an all-time high on Tuesday, but before Friday's gains, the stock had been pulling back for a couple of sessions. Palantir and other artificial intelligence companies benefited from upbeat sentiment after earnings results from chipmaker Broadcom (AVGO) revealed strong AI demand. Moderna (MRNA) shares wrapped up a volatile week of trading with a gain of 5.1% on Friday. The biotech company announced at the end of last week that it had received Food and Drug Administration (FDA) approval for the use of its new COVID-19 vaccine by older and higher-risk patients. On Tuesday, Health and Human Services Secretary Robert F. Kennedy Jr. said Moderna had agreed to a placebo-controlled trial of the vaccine. United Airlines (UAL) announced a partnership with Spotify Technology (SPOT) that will allow airborne passengers to access playlists, audiobooks, and video podcasts from the streaming service on their seatback screens. United shares increased 4.8% on Friday, while rival carrier Delta Air Lines (DAL) shares were up 4.3%. Tesla (TSLA) shares advanced 3.7% on Friday as the feud between Tesla CEO Elon Musk and U.S. President Donald Trump showed signs of de-escalation heading into the weekend. The spat between the two contributed to a major drop in the electric vehicle (EV) maker's stock in the prior session. Several analysts reaffirmed their bullishness on Tesla despite the high-profile conflict, but they noted that the tensions with Trump could complicate the regulatory path for the firm's self-driving technology or risk alienating people with certain political perspectives. Lululemon Athletica (LULU) issued lower-than-expected sales and profit guidance for the current quarter and trimmed its full-year profit forecast. The maker of yoga attire and other athletic apparel noted that U.S. consumers are taking a cautious approach to spending and discussed plans to increase prices on some products as it aims to mitigate tariff impacts. Lululemon shares plunged 19.8% on Friday, dropping the most of any constituent in the S&P 500. JPMorgan and UBS analysts cut their price targets on Lululemon stock following the underwhelming outlook. Broadcom posted fiscal second-quarter sales and adjusted profit results that were roughly in line with consensus forecasts. A major year-over-year uptick in artificial intelligence semiconductor revenue helped the chipmaker achieve record quarterly revenue of $15 billion. However, Broadcom shares slipped 5% on Friday, receding from a string of record highs notched before the earnings release. Mosaic (MOS), a provider of fertilizers and other agricultural products, reduced its 2025 phosphate production guidance, citing operational issues at its U.S. facilities. Shares of Mosaic were down 4.4%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
